In particular, in two early studies (159, 160) a WT1 peptide vaccine was capable of inducing WT1-specific cytotoxic CD8+ T cells, which was associated with some clinical responses, including stabilization of leukemia and achievement of MRD negativity. Here, WT1 is linked to leukemia.